N. Sasson

发表

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study

D. Arkadir, W. Poewe, Nir Giladi, 2021, Movement disorders : official journal of the Movement Disorder Society.

CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

M. Filippi, X. Montalban, P. Vermersch, 2021, Multiple sclerosis.

Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree

G. Cutter, V. Knappertz, D. Ladkani, 2016, BMC Neurology.

ARPEGGIO: A randomized, placebo-controlled study to evaluate oral laquinimod in patients with primary progressive multiple sclerosis (PPMS) (P7.210)

F. Barkhof, M. Sormani, X. Montalban, 2015 .

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

X. Montalban, L. Kappos, G. Comi, 2017, International journal of MS care.

ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

Nir Giladi, R. Djaldetti, T. Gurevich, 2021, Parkinsonism & related disorders.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

D. Arnold, P. Sørensen, F. Zipp, 2014, Journal of Neurology.

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO‐B) Inhibitor Rasagiline

L. Adar, N. Sasson, T. Goren, 2010, Journal of clinical pharmacology.

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.

D. Arnold, F. Zipp, E. Havrdová, 2014, Journal of neurology.

Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO‐B) Inhibitor Rasagiline

L. Adar, N. Sasson, T. Goren, 2010, Journal of clinical pharmacology.